Cargando…

SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis

INTRODUCTION: The COVID-19 pandemic is a major global public health crisis. More than 2 years into the pandemic, effective therapeutic options remain limited due to rapid viral evolution. Stemming from the emergence of multiple variants, several monoclonal antibodies are no longer suitable for clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liew, Mabel Nyit Yi, Kua, Kok Pim, Lee, Shaun Wen Huey, Wong, Kon Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494534/ https://www.ncbi.nlm.nih.gov/pubmed/37701439 http://dx.doi.org/10.3389/fimmu.2023.1100263

Ejemplares similares

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
por: Westendorf, Kathryn, et al.
Publicado: (2022)

N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence
por: Wong, Kon Ken, et al.
Publicado: (2021)

Randomized trials of housing interventions to prevent malaria and Aedes-transmitted diseases: A systematic review and meta-analysis
por: Kua, Kok Pim, et al.
Publicado: (2021)

Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest
por: Gearges, Christina, et al.
Publicado: (2022)

Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
por: McCreary, Erin K, et al.
Publicado: (2022)

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
por: Alcantara, Mellissa C., et al.
Publicado: (2023)

Association Between Cytomegalovirus Infection and Tuberculosis Disease: A Systematic Review and Meta-Analysis of Epidemiological Studies
por: Kua, Kok Pim, et al.
Publicado: (2022)

Complementary and alternative medicine for the treatment of bronchiolitis in infants: A systematic review
por: Kua, Kok Pim, et al.
Publicado: (2017)

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
por: Shrestha, Lok Bahadur, et al.
Publicado: (2021)

The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Luo, Jie, et al.
Publicado: (2023)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
por: Wang, Ruoke, et al.
Publicado: (2022)

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
por: Shan, Sisi, et al.
Publicado: (2021)

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
por: Pande, Kalyan, et al.
Publicado: (2022)

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2
por: Konwarh, Rocktotpal
Publicado: (2020)

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
por: Han, Xiaojian, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
por: Niu, Ling, et al.
Publicado: (2021)

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
por: Schlickeiser, Stephan, et al.
Publicado: (2021)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
por: Zhang, Lu, et al.
Publicado: (2022)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
por: Bullen, Georgia, et al.
Publicado: (2021)

Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection
por: Wieczorek, Lindsay, et al.
Publicado: (2022)

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic
por: Nichols, Russell M, et al.
Publicado: (2022)

Neutralizing SARS-CoV-2
por: Poeschla, Eric
Publicado: (2020)

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
por: Hentzien, Maxime, et al.
Publicado: (2022)

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
por: Yue, Shuai, et al.
Publicado: (2021)

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
por: Lee, Sua, et al.
Publicado: (2021)

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization
por: Tang, Haijun, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications
por: Schlör, Anja, et al.
Publicado: (2022)

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
por: Abebe, Endeshaw Chekol, et al.
Publicado: (2023)

Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
por: Du, Wenjuan, et al.
Publicado: (2023)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
por: Liu, Zheng, et al.
Publicado: (2022)

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2021)

Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19
por: Kapur, Rohan, et al.
Publicado: (2023)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants
por: Lunderberg, Justin Mark, et al.
Publicado: (2022)

A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants
por: Egia-Mendikute, Leire, et al.
Publicado: (2022)

Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay
por: Liu, Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7erpe2ri4c5cu1qtupfsqhfb0d